Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BeiGene Starts China Clinical Trial of Melanoma Drug

publication date: Aug 4, 2015
BeiGene, an innovative Beijing oncology pharma, received CFDA approval to conduct China Phase I clinical trials of BGB-283, a novel RAF dimer inhibitor. BeiGene will test the drug in solid tumors with B-RAF mutations or other aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway; one of the major targets will be melanoma. In 2003, BeiGene out-licensed ex-China rights for BGB-283 to Merck Serono in a $233 million deal. BeiGene began a trial of the drug candidate in Australia in December 2003 More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital